Viridian Therapeutics is primarily focused on the research, development, and commercialization of therapies for Thyroid Eye Disease (TED). The company's lead product candidate, veligrotug (VRDN-001), is a humanized monoclonal anti-IGF-1R antibody. Research and development activities include clinical trials (Phase 3 THRIVE trial), preclinical studies, and manufacturing process development. The company utilizes advanced antibody engineering and formulation technologies. The therapeutic area is TED, a serious autoimmune disease causing vision impairment and disfigurement. The patient impact is significant, aiming to improve vision, reduce inflammation, and enhance the quality of life for TED patients. Viridian's market positioning is centered on being a leader in TED treatment, with a focus on innovative therapies. Future opportunities include expanding the application of their technology to other autoimmune diseases. Regulatory and clinical aspects involve FDA approval processes and adherence to clinical trial protocols. Partnerships include collaborations with drug delivery innovators like Enable Injections and Ypsomed AG for autoinjector pen device customization and supply.